ArticleFrontiers in cellular and infection microbiology2025
Garcinone C inhibits pseudorabies virus replication through EGF/PI3K/Akt axis.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pseudorabies virus (PRV), a significant pathogen of swine, causes substantial economic losses, and even poses an emergent public health concern due to its zoonotic potential. The continuous evolution of PRV has undermined the effectiveness of current vaccines and antiviral drugs. Consequently, there is an urgent need to develop novel strategies to curb its spread. Methods: The inhibitory effect of garcinone C on PRV replication was assessed Results: In the study, we found that garcinone C inhibited PRV replication in a concentration- and timedependent manner in vitro. The antiviral activity of garcinone C was specific to post-infection administration and did not extend to pre-treatment and cotreatment conditions. Transcriptomic analysis identified DEGs between garcinone C- and vehicle-treated cells after PRV infection. KEGG pathway enrichment analysis of the DEGs indicated that the antiviral effect of garcinone C was primarily associated with the PI3K-Akt signaling pathway, potentially through the downregulation of the host epidermal growth factor. Furthermore, garcinone C suppressed the production of key inflammatory cytokines such as IL-6, IL-8, and TNF-a during PRV infection. Oral administration of garcinone C conferred protection in PRVinfected mice, leading to attenuated weight loss, an improved survival rate, as well as reduced pathological changes and viral loads in tissues. Discussion: Collectively, our findings identify garcinone C as a promising therapeutic candidate against PRV and elucidate its underlying molecular mechanism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.